12:00 AM
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SCIB1: Phase I/II ongoing

Scancell said a cohort review committee recommended the continuation of the Phase I portion of an open-label, U.K. Phase I/II trial based on a review of safety data from the second group of 3 patients receiving 2 mg SCIB1....

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >